Autopsy report · NCT01965834

Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma

“Lack of adequate accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months after it had already started.
• Ran for about 3 years 7 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Miami

Sponsor type

University, hospital or other

Conditions

Multiple Myeloma

Interventions

Fenofibrate

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
  “Lack of accrual” (92% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (88% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (86% match in meaning)
• Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
  “Due to poor accrual” (84% match in meaning)
• Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
  “Due to low accrual” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.